Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

THE TRUTH ABOUT: Regeneron s gene therapy shows significant gains in genetic hearing loss - Caught on Camera

Tarrytown,,Ny,-,March,21,,2020,-,This,Week,Regeneron

On Sunday, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) unveiled updated data from its investigational gene therapy DB-OTO for profound genetic hearing loss caused by variants of the otoferlin (OTOF) gene.

The New England Journal of Medicine published the report. The annual American Academy of Otolaryngology-Head and Neck Surgery meeting presented the data.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.